Suchergebnisse - "Kapp-Schwoerer, Silke"

PubPharm (19)

1

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

enthalten in: Journal of hematology & oncology | 2023

von Heitmann, J. | Schlenk, R. | Dörfel, D. | +15

2

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

enthalten in: Journal of hematology & oncology | 2023

von Heitmann, J. | Schlenk, R. | Dörfel, D. | +15

3

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

enthalten in: Journal of hematology & oncology | 2023

von Heitmann, J. | Schlenk, R. | Dörfel, D. | +15

4

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

enthalten in: Journal of hematology & oncology | 17 August 2023

von Heitmann, J. | Schlenk, R. | Dörfel, D. | +15

5

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09) : a randomised, open-label, multicentre, phase 3 trial

enthalten in: The Lancet. Haematology | 2023

von Döhner, H. | Weber, D. | Krzykalla, J. | +72

CommentIn: Lancet Haematol. 2023 Jul;10(7):e478-e479. - PMID 37187197

6

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09) : a randomised, open-label, multicentre, phase 3 trial

enthalten in: The lancet / Haematology | July 2023

von Döhner, H. | Weber, D. | Krzykalla, J. | +34

7

Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults : an update of the literature

enthalten in: Expert opinion on pharmacotherapy | 2022

von Grunenberg, A. | Sala, E. | Kapp-Schwoerer, S. | +1

8

18F-FDG-PET/MR in Alveolar Echinococcosis : Multiparametric Imaging in a Real-World Setting

enthalten in: Pathogens (Basel, Switzerland) | 2022

von Eberhardt, N. | Peters, L. | Kapp-Schwoerer, S. | +4

9

Venetoclax - Standard in der Erstlinientherapie unfitter AML-Patienten

Erschienen: Stuttgart, Thieme, August 2022

Case Report

von Klaiber-Hakimi, M. | Kapp-Schwoerer, S.

10

Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin

enthalten in: Haematologica | 2021

von Teich, K. | Krzykalla, J. | Kapp-Schwoerer, S. | +16

CommentIn: Haematologica. 2021 Nov 01;106(11):2796-2798. - PMID 34092060